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and procedural coping skills. To minimize related donor distress, a
multidisciplinary team worked to develop a “Donor Recognition
Program” which includes acknowledgement, education, counsel-
ing, and support. All donors will receive a specially designed T-
shirt. Minor donors will undergo pre- and post-procedure coun-
seling, and will have a needs assessment at 2, 4, 6, and 12 months
post-donation to determine issues and facilitate adjustment related
to donation and recipient outcome. Baseline and 1 year post do-
nation measures of behavior, anxiety, and esteem for minor par-
ticipants will be compared to evaluate the program. For adults, a
donor questionnaire will be developed, tested, reﬁned and distrib-
uted to related donors at the time of donation, two weeks after
donation and two months after the patient is transplanted. The
results of this questionnaire will be used to evaluate the need for
creating additional adult donor services and/or to reﬁne practices
and processes at this institution.
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HEART SUCCESS WITH BLOOD & MARROW TRANSPLANT PATIENTS: A
MULTIDISCIPLINARY APPROACH FOR CONGESTIVE HEART FAILURE
PATIENTS
Meyers, A.L.1, Trueman, A.1, Johnston, P.1, Woods, M.1, Fadol, A.1,
Oliver, T.1, Martin, A.1 1MD Anderson Cancer Center, Houston, TX.
By 2010 it is estimated that the American population aged 65 and
older will increase to over 40 million individuals. This increase is
already evident in our Blood and Marrow transplant population
with an older population being transplanted with increased survival
rates post transplant. Increased age translates into co-morbid con-
ditions that contribute to a signiﬁcant proportion of morbidity and
mortality. One example of this includes cardiovascular conditions
that patients bring with them at an increasing rate as they advance
in age. The average rates of cardiovascular events rise from 7 per
1,000 men ages 35-44 to 68 per 1,000 men ages 85-94 with
narrowing gaps with advancing age and comparable rates occur 10
years later in life for women.
Congestive heart failure (CHF) is one of those cardiovascular
co-morbid conditions that this patient population continues to
bring into the transplant setting or is developed as a result of
treatment. CHF affects 1.5-2% of the population and increases
6-10% in people greater than 65 years of age. In 2005, more than
400 patients were hospitalized at the comprehensive cancer center
with a discharge diagnosis of CHF totaling a cost of 36 million
dollars. Cancer patients with heart failure can have improved
clinical outcomes.
To improve clinical outcomes of these patients, we have teamed
together with cardiology and have implemented a Heart Success
Program on the 52-bed inpatient unit. The program entails education
of the staff and patients about the symptoms of CHF, the importance
of daily weights, medications, walking, energy conservation, and nu-
trition. The program is a multidisciplinary approach including Phar-
macy, APN’s, Nursing, Rehabilitation services, Social Work, Case
Management, andNutrition. The goals for the staff utilizing the heart
success program include increasing the nurses’ awareness of the
pathophysiology and pharmacology of CHF, being more proactive in
its recognition, and identifying patients eligible for the program. The
overall goals are to have a reduction in hospital admissions for heart
failure exacerbation, decrease the length of stay and healthcare dollars
spent. Weekly rounds are conducted with Cardiology and the multi-
disciplinary team to review the CHF patients and their treatment. In
addition, a monthly meeting is held with Heart Success members to
look at the data from these patients to evaluate treatment outcomes. A
case will be presented.
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NURSING CARE OF THE CHILD RECEIVING INHALED RIBAVIRIN FOR
THE TREATMENT OF RSV IN THE PERITRANSPLANT PERIOD
Murphy, C.1, Frey, M.1, Kurtzberg, J.1 1Duke University Hospital,
Durham, NC; The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Children status post blood and marrow transplantation have
poor immune function putting them at high risk for serious viral
infections of the respiratory tract. RSV, Parainﬂuenza and Ad-
enovirus can cause serious infections in these patients. First line
therapy generally includes IVIG and supportive care. Synagis
can be used to prevent RSV if the potential for exposure is
known in advance of the infection. Ribavirin is an antiviral agent
that can be used in the post BMT patient who contracts RSV.
There is some data to suggest Ribavirin also has activity against
Parainﬂuenza types 1, 2 and 3, and Adenovirus. The criteria for
administration of inhaled Ribavirin are persistent infection de-
spite appropriate treatment and if there is evidence of lower
respiratory infection manifested by pulmonary inﬁltrates, oxy-
gen requirements or respiratory distress. Special precautions
must be taken when caring for a child receiving Ribavirin via
inhalation. Of special concern is the risk of exposure to the
family and caregiver. Inhaled Ribavirin is often poorly tolerated
and the administration of this therapy requires careful planning.
The purpose of this abstract is to describe the indications and
side effects of inhaled Ribavirin. The nursing care associated
with patients receiving inhaled Ribavirin will also be presented.
Speciﬁc goals will be to describe the administration techniques
and safety precautions that must be taken by caregivers and staff.
397
USE OF N-ACETYLCYSTEINE FOR HEPATIC VENO-OCCLUSIVE DISEASE
PROPHYLAXIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANT PATIENTS
Englert, L.1, Murphy, P.1, Quinn, M.1, Tat, C.1 1UCSF Children’s
Hospital, San Francisco, CA.
Background: Veno-occlusive disease (VOD) of the liver is one
of the early complications following hematopoietic stem cell trans-
plantation (HSCT) due to liver damage caused by pre-transplant
chemotherapy and/or total body radiation. The incidence of VOD
in the pediatric HSCT population is approximately 25% with 80%
of those having mild to moderate disease only requiring supportive
measures and 20% developing severe disease. The mortality rate is
as high as 50% for those who develop severe VOD. In a study
conducted at UCSF Children’s Hospital from March 2002
through June 2005, 12% of patients who received myeloablative
conditioning regimens developed VOD. Of those, 62% had mild/
moderate disease, 38% had severe, and 3% died from VOD. The
Pediatric Bone Marrow Transplant (PBMT) Program at UCSF
Children’s Hospital has experience using ﬁbrinolytic agents and/or
an anticoagulant for treatment of severe VOD to target the clot-
ting phenomenon. However, prophylaxis for VOD is still ques-
tionable and not well studied. N-Acetylcysteine (NAC) is currently
approved for use as a mucolytic agent in certain pulmonary disor-
ders and as an antidote for acetaminophen overdose. Evidence thus
far has shown its potential beneﬁts in preventing VOD in patients
undergoing HSCT without affecting the desired effects of condi-
tioning regimens.
Methods: Using the group from our initial study of VOD as our
control, we conducted a retrospective review of 17 patients who
received NAC between 2005-2006. Both groups were treated with
similar myeloablative conditioning regimens. We compared the
incidence of VOD in the two groups. For the NAC group, NAC
100 mg/kg/dose was given IV over 2 hours on day of admission,
Day 1 and Day 2 post-transplant (a fourth dose was given to
patients who received Busulfan/Cyclophosphamide combination
therapy).
Results: Results to be presented at the 2007 BMT Tandem
Meetings.
Conclusion: The use of NAC in the pediatric HSCT population
is a novel approach to preventing severe VOD, but requires pro-
spective studies to be conducted. Administration of NAC during
the pre and post transplant period increases nurse education and
awareness to the risks of VOD and gives them the opportunity to
participate in research that may improve their patients’ transplant
outcomes.
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